DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8373cx/the) has announced the addition of the "The Pharmaceutical Market: New Zealand" report to their offering.
Low growth potential in New Zealand's pharmaceutical market will attract risk-averse investors. However, we note that regulatory delays in funding new medicines will hinder patients' access to pharmaceuticals, constituting a downside risk for drug companies looking to sell their products in the country.
Risk/Reward Rating:
New Zealand was ranked 10th out of 18 pharmaceutical markets surveyed in the Asia region in Q1. Its score is dragged down by a low industry rewards score, due to its small and relatively low-growth potential market, and a low industry risks score because of its regulatory processes. In terms of Rewards, New Zealand is rated highly thanks to a stable economic and political environment and developed regulatory regimen.
Competitive Landscape:
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Companies Mentioned
- Douglas Pharmaceuticals
- New Zealand Pharmaceuticals
- Southern Cross Healthcare Group
For more information visit http://www.researchandmarkets.com/research/8373cx/the
